SCHEMBL24895604

SCHEMBL24895604

CCC(C(=O)OC)c1ccnc(SC)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
ACACB O00763 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
SYK P43405 1/20 0.36
ALOX15 P16050 1/20 0.35
POLB P06746 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
CCNA2 P20248 2/20 0.35
CDK2 P24941 2/20 0.35
CDK5 Q00535 2/20 0.35
CDK5R1 Q15078 2/20 0.35
DYRK1A Q13627 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
KMT2A Q03164 3/20 0.35
MAPK9 P45984 1/20 0.34
MAPK10 P53779 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23121391 0.84 ALOX15 (0.41) ALDH1A1ACACBALOX15POLBTDP1
SCHEMBL21392138 0.80 FFAR2 (0.38) L3MBTL1KMT2ASMN1; SMN2RAB9AMEN1
SCHEMBL31515051 0.80 FFAR2 (0.38) L3MBTL1KMT2ASMN1; SMN2RAB9AMEN1
SCHEMBL17601005 0.77 IDH1 (0.44) ACACBL3MBTL1ALOX15CCNA2CDK2
SCHEMBL31422607 0.75 KMT2A (0.40) ALDH1A1SYKALOX15POLBTDP1
SCHEMBL29791248 0.75 LMNA (0.43) ALDH1A1ACACBL3MBTL1ALOX15CCNA2
SCHEMBL24895775 0.75 LMNA (0.43) ALDH1A1ACACBL3MBTL1ALOX15CCNA2
SCHEMBL1914533 0.74 L3MBTL1 (0.54) ALDH1A1ACACBL3MBTL1ALOX15POLB
SCHEMBL6950821 0.73 ALOX15 (0.36) ALDH1A1ACACBL3MBTL1SYKALOX15
SCHEMBL26114220 0.73 ALDH1A1 (0.39) ALDH1A1SYKALOX15POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230020663-A1 SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS STEP PHARMA S.A.S. (FR) 2023-01-19 US disclosed
US-20230020663-A1 SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS STEP PHARMA S.A.S. (FR) 2023-01-19 US disclosed
EP-4041715-A1 SULFONAMIDE INHIBITORS AS CTPS 1 INHIBITORS Step Pharma S.A.S. (FR) 2022-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020663-A1 SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS CTPS1, CTPS2, TYMS ALDH1A1 1517/4885ACACB 354/4885L3MBTL1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.